Genetic background of urinary incontinence - state-of-the-art and perspectives

• Autorzy: Stangel-Wójcikiewicz K. , Piwowar M.

Identyfikatory

DOI

10.1515/bams-2015-0027

• Języki publikacji: EN

Abstrakty

EN

The paper presents an overview of the current studies attempting to determine the genetic background of urinary incontinence (UI) problems. The overview referred to the adaptations of biomedical literature from Medline, life science journals, and online books were searched from the earliest date possible to March 2015. Genetic variability studies (mostly with the use of single nucleotide polymorphism) in the context of UI are discussed. The authors indicate the variability of polymorphic forms of proteins, whose modified function may be related to the observed phenotypic symptoms: UI. The paper includes a discussion of the varied level of gene expression and the issue of defective process of the development of the urinary system in the context of UI disorders. The literature does not present any general, unequivocal description of the relationship between the genetic background and phenotype as UI. It is suggested that the methods of integration of data from various techniques (e.g. high throughputs) in reference to social, demographic, and other data may be the way of the approach used for the effective description of the relationship between genetic background and observed UI.

Słowa kluczowe

EN

genetic association studies; genetic variation; urinary incontinence

• Wydawca: Uniwersytet Jagielloński - Collegium Medicum ; Index Copernicus Sp. z o.o.
• Czasopismo: Bio-Algorithms and Med-Systems
• Rocznik: 2015
• Tom: Vol. 11, no. 4
• Strony: 197--203
• Opis fizyczny: Bibliogr. 49 poz., rys.

Twórcy

autor

Stangel-Wójcikiewicz K.

• Department of Gynaecology and Oncology, Jagiellonian University Collegium Medicum, Cracow, Poland

autor

Piwowar M.

• Bioinformatics and Telemedicine, Jagiellonian University Collegium Medicum, Kopernika 16, 31-501 Cracow, Poland

Bibliografia

• 1. Norton P, Brubaker L. Urinary incontinence in women. Lancet 2006;367:57–67.
• 2. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012;10:CD001405.
• 3. Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009;360:481–90.
• 4. Sangsawang B, Sangsawang N. Stress urinary incontinence in pregnant women: a review of prevalence, pathophysiology, and treatment. Int Urogynecol J 2013;24:901–12.
• 5. Wennberg A-L, Altman D, Lundholm C, Klint A, Iliadou A, Peeker R, et al. Genetic influences are important for most but not all lower urinary tract symptoms: a population-based survey in a cohort of adult Swedish twins. Eur Urol 2011;59:1032–8.
• 6. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013;41:D808–15.
• 7. Altman D, Forsman M, Falconer C, Lichtenstein P. Genetic influence on stress urinary incontinence and pelvic organ prolapse. Eur Urol 2008;54:918–23.
• 8. Ertunc D, Tok EC, Pata O, Dilek U, Ozdemir G, Dilek S. Is stress urinary incontinence a familial condition? Acta Obstet Gynecol Scand 2004;83:912–6.
• 9. Rohr G, Kragstrup J, Gaist D, Christensen K. Genetic and environmental influences on urinary incontinence: a Danish population-based twin study of middle-aged and elderly women. Acta Obstet Gynecol Scand 2004;83:978–82.
• 10. McKenzie P, Rohozinski J, Badlani G. Genetic influences on stress urinary incontinence. Curr Opin Urol 2010;20:291–5.
• 11. Stothers L, Friedman B. Risk factors for the development of stress urinary incontinence in women. Curr Urol Rep 2011;12:363–9.
• 12. Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010;467:52–8.
• 13. Dar P, Curnow KJ, Gross SJ, Hall MP, Stosic M, Demko Z, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol 2014;211:527.e1–17.
• 14. Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, Cotsapas C, et al. Genome-wide detection and characterization of positive selection in human populations. Nature 2007;449:913–8.
• 15. Piwowar M. Elementy Informatyki Medycznej, Genomika. I. Jagiellonian University Press, 2012.
• 16. Skorupski P, Król J, Starega J, Adamiak A, Jankiewicz K, Rechberger T. An alpha-1 chain of type I collagen Sp1-binding site polymorphism in women suffering from stress urinary incontinence. Am J Obstet Gynecol 2006;194:346–50.
• 17. Sioutis D, Economou E, Lambrinoudaki I, Tsamadias V, Creatsa M, Liapis A. Sp1 collagen I A1 polymorphism in women with stress urinary incontinence. Int Urogynecol J 2011;22:835–9.
• 18. Noronha JA, Schwanke CH, Machado DC, Braga R, Lubianca JM, Sesti FL, et al. Association between T102C polymorphism of serotonin 2A receptor gene and urinary incontinence in older women. J Invest Med 2010;58:32–7.
• 19. Schwanke CH, Bittencourt L, Noronha JA, Augustin SA, Jung IE, Cruz IB. Is there an association between T102C polymorphism of the serotonin receptor 2A gene and urinary incontinence? Braz J Med Biol Res 2007;40:1315–22.
• 20. Skorupski P, Miotła P, Jankiewicz K, Rechberger T. MMP-1 and MMP-3 gene encoding polymorphism and the risk of the development of pelvic organ prolapse and stress urinary incontinence. Ginekol Pol 2010;81:594–9.
• 21. Allen-Brady K, Norton PA, Farnham JM, Teerlink C, Cannon-Albright LA. Significant linkage evidence for a predisposition gene for pelvic floor disorders on chromosome 9q21. Am J Hum Genet 2009;84:678–82.
• 22. Norton P, Milsom I. Genetics and the lower urinary tract. Neurourol Urodyn 2010;29:609–11.
• 23. Lin G, Shindel AW, Banie L, Deng D, Wang G, Hayashi N, et al. Molecular mechanisms related to parturition-induced stress urinary incontinence. Eur Urol 2009;55:1213–22.
• 24. Kim J, Lin B, Kim S, Choi B, Evseenko D, Lee M. TGF-β1 conjugated chitosan collagen hydrogels induce chondrogenic differentiation of human synovium-derived stem cells. J Biol Eng 2015;9:1.
• 25. Adra S, Sun T, MacNeil S, Holcombe M, Smallwood R. Development of a three dimensional multiscale computational model of the human epidermis. PLoS One 2010;5:e8511.
• 26. Ishiguro N, Kojima T. Role of aggrecanase and MMP in cartilage degradation. Clin Calcium 2004;14:38–44.
• 27. Takaishi H, Kimura T, Dalal S, Okada Y, D’Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 2008;9:47–54.
• 28. Gao P, Yang J-L, Zhao H, You J-H, Hu Y. Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: a meta-analysis. Tumour Biol 2014;35:10137–48.
• 29. Zhang P, Mende U. Functional role, mechanisms of regulation, and therapeutic potential of regulator of G protein signaling 2 in the heart. Trends Cardiovasc Med 2014;24:85–93.
• 30. Tsang S, Woo AY-H, Zhu W, Xiao R-P. Deregulation of RGS2 in cardiovascular diseases. Front Biosci (Schol Ed) 2010;2:547–57.
• 31. National Collaborating Centre for Women’s and Children’s Health (UK). Urinary incontinence in women: the management of urinary incontinence in women. London: Royal College of Obstetricians and Gynaecologists (UK), 2013.
• 32. Samuelsson E, Odeberg J, Stenzelius K, Molander U, Hammarström M, Franzen K, et al. Effect of pharmacological treatment for urinary incontinence in the elderly and frail elderly: a systematic review. Geriatr Gerontol Int 2015;15:521–34.
• 33. Masumori N, Tsukamoto T, Yanase M, Horita H, Aoki M. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol 2010:205251.
• 34. Füsgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000;38:223–34.
• 35. Yono M, Yoshida M, Wada Y, Kikukawa H, Takahashi W, Inadome A, et al. Pharmacological effects of tolterodine on human isolated urinary bladder. Eur J Pharmacol 1999;368:223–30.
• 36. Noguchi K, Yamagishi T, Suzuki K, Kondo K, Kishida T, Saito K, et al. [Propiverine hydrochloride improved correlatively subjective QOL and objective findings in Japanese patients with urinary frequency and/or incontinence]. Hinyokika Kiyo. 2006;52:343–8 (Japanese).
• 37. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999;39:289–96.
• 38. Baillie TA, Rettie AE. Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet 2011;26:15–29.
• 39. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1–16.
• 40. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251–63.
• 41. Lee CR. CYP2C9 genotype as a predictor of drug disposition in humans. Methods Find Exp Clin Pharmacol 2004;26:463–72.
• 42. Hsu JW, Wang YC, Lin CC, Bai YM, Chen JY, Chiu HJ, et al. No evidence for association of alpha 1a adrenoceptor gene polymorphism and clozapine-induced urinary incontinence. Neuropsychobiology 2000;42:62–5.
• 43. Kröger E, Van Marum R, Souverein P, Carmichael P-H, Egberts T. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiol Drug Saf 2015;24:276–85.
• 44. Thongboonkerd V. Genomics, proteomics and integrative “omics” in hypertension research. Curr Opin Nephrol Hypertens 2005;14:133–9.
• 45. Peterlin B, Maver A. Integrative “omic” approach towards understanding the nature of human diseases. Balkan J Med. Genet 2012;15:45–50.
• 46. Stangel-Wojcikiewicz K, Jarocha D, Piwowar M, Jach R, Uhl T, Basta A, et al. Autologous muscle-derived cells for the treatment of female stress urinary incontinence: a 2-year follow-up of a Polish investigation. Neurourol Urodyn 2014;33:324–30.
• 47. Stangel-Wójcikiewicz K, Piwowar M, Migdał M, Skotniczny K. Virtual patient case: study of a urinary incontinence therapy procedure in a woman. Bio-Algorithms Med-Syst 2014;10:151–7.
• 48. Hart ML, Izeta A, Herrera-Imbroda B, Amend B, Brinchmann JE. Cell therapy for stress urinary incontinence. Tissue Eng Part B Rev 2015;21:365–76.
• 49. Robertson B, Harding KE. Outcomes with individual versus group physical therapy for treating urinary incontinence and low back pain: a systematic review and meta-analysis of randomized controlled trials. Arch Phys Med Rehabil 2014;95:2187–98.